D S Greene - JoVE Visualize

Showing results (41-50 of 51) with videos related to

Pageof 6

Sort By:

Journal of Clinical Pharmacology|May 29, 1998

Lack of effect of food on the oral bioavailability of irbesartan in healthy male volunteersN N Vachharajani, W C Shyu, S Mantha, et al.

Pharmaceutical Research|November 1, 1995

Absorption and presystemic metabolism of nefazodone administered at different regions in the gastrointestinal tract of humansP H Marathe, D E Salazar, D S Greene, et al.

Journal of Clinical Pharmacology|September 2, 1998

Oral bioavailability and disposition characteristics of irbesartan, an angiotensin antagonist, in healthy volunteersN N Vachharajani, W C Shyu, T J Chando, et al.

Clinical Pharmacology and Therapeutics|October 1, 1995

Single- and multiple-dose pharmacokinetics of nefazodone in patients with hepatic cirrhosisR H Barbhaiya, U A Shukla, C S Natarajan, et al.

Drug Metabolism and Disposition: the Biological Fate of Chemicals|July 20, 2000

Disposition of radiolabeled ifetroban in rats, dogs, monkeys, and humansR C Dockens, K S Santone, J G Mitroka, et al.

Pharmaceutical Research|July 1, 1997

Assessment of dose proportionality, absolute bioavailability, and immunogenicity response of CTLA4Ig (BMS-188667), a novel immunosuppressive agent, following subcutaneous and intravenous administration to ratsN R Srinivas, W C Shyu, R S Weiner, et al.

Journal of Clinical Pharmacology|October 1, 1995

Safety, tolerance, and preliminary pharmacokinetics of nefazodone after administration of single and multiple oral doses to healthy adult male volunteers: a double-blind, phase I studyR H Barbhaiya, P H Marathe, D S Greene, et al.

Clinical Pharmacology and Therapeutics|January 1, 1992

Single-dose pharmacokinetics of piperacillin and tazobactam in patients with renal diseaseC A Johnson, C E Halstenson, J S Kelloway, et al.

Journal of Pharmaceutical Sciences|March 1, 1996

A pharmacokinetic study of intravenous CTLA4Ig, a novel immunosuppressive agent, in miceN R Srinivas, R S Weiner, W C Shyu, et al.

Journal of Pharmaceutical Sciences|January 1, 1996

Pharmacokinetics and pharmacodynamics of CTLA4lg (BMS-188667), a novel immunosuppressive agent, in monkeys following multiple dosesN R Srinivas, R S Weiner, G Warner, et al.

Pageof 6

Showing results (41-50 of 51) with videos related to

Sort By:

Pageof 6

Journal of Clinical Pharmacology|May 29, 1998

Lack of effect of food on the oral bioavailability of irbesartan in healthy male volunteersN N Vachharajani, W C Shyu, S Mantha, et al.

Pharmaceutical Research|November 1, 1995

Absorption and presystemic metabolism of nefazodone administered at different regions in the gastrointestinal tract of humansP H Marathe, D E Salazar, D S Greene, et al.

Journal of Clinical Pharmacology|September 2, 1998

Oral bioavailability and disposition characteristics of irbesartan, an angiotensin antagonist, in healthy volunteersN N Vachharajani, W C Shyu, T J Chando, et al.

Clinical Pharmacology and Therapeutics|October 1, 1995

Single- and multiple-dose pharmacokinetics of nefazodone in patients with hepatic cirrhosisR H Barbhaiya, U A Shukla, C S Natarajan, et al.

Drug Metabolism and Disposition: the Biological Fate of Chemicals|July 20, 2000

Disposition of radiolabeled ifetroban in rats, dogs, monkeys, and humansR C Dockens, K S Santone, J G Mitroka, et al.

Pharmaceutical Research|July 1, 1997

Assessment of dose proportionality, absolute bioavailability, and immunogenicity response of CTLA4Ig (BMS-188667), a novel immunosuppressive agent, following subcutaneous and intravenous administration to ratsN R Srinivas, W C Shyu, R S Weiner, et al.

Journal of Clinical Pharmacology|October 1, 1995

Safety, tolerance, and preliminary pharmacokinetics of nefazodone after administration of single and multiple oral doses to healthy adult male volunteers: a double-blind, phase I studyR H Barbhaiya, P H Marathe, D S Greene, et al.

Clinical Pharmacology and Therapeutics|January 1, 1992

Single-dose pharmacokinetics of piperacillin and tazobactam in patients with renal diseaseC A Johnson, C E Halstenson, J S Kelloway, et al.

Journal of Pharmaceutical Sciences|March 1, 1996

A pharmacokinetic study of intravenous CTLA4Ig, a novel immunosuppressive agent, in miceN R Srinivas, R S Weiner, W C Shyu, et al.

Journal of Pharmaceutical Sciences|January 1, 1996

Pharmacokinetics and pharmacodynamics of CTLA4lg (BMS-188667), a novel immunosuppressive agent, in monkeys following multiple dosesN R Srinivas, R S Weiner, G Warner, et al.

Pageof 6